BACKGROUND: Our findings strongly suggest that CKS1B plays a critical role in PDAC progression, stemness and chemoresistance. Targeting the FOXM1-CKS1B axis represents a promising therapeutic strategy for PDAC patients.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: